ProBio Tackles Gene Therapy Bottleneck with New Rapid Test

HOPEWELL, NJ – May 04, 2026 – ProBio Inc. has launched a new service aimed at a critical weak point in the development of next-generation medicines: the early-stage manufacturing of viral vectors. The company's new Viral Vector Packaging Test, announced today, is designed to give biopharmaceutical innovators crucial data within weeks, potentially shaving months or years off the arduous journey from laboratory discovery to clinical reality for cell and gene therapies (CGT).

This offering enters a field where the promise of revolutionary cures is often tempered by staggering development costs and high failure rates. By providing a rapid, data-rich assessment of a therapy's manufacturability, ProBio aims to de-risk one of the most uncertain phases of drug development.

Navigating the 'Valley of Death' in Gene Therapy

The path to bringing a cell or gene therapy to patients is notoriously difficult. A significant portion of this challenge lies not in the initial scientific discovery, but in the complex manufacturing process. Industry data reveals a daunting reality: an estimated 40% of Investigational New Drug (IND) applications are stalled or rejected due to issues with Chemistry, Manufacturing, and Controls (CMC), the discipline focused on ensuring product quality and consistency. Furthermore, between 2020 and 2024, nearly three-quarters of FDA rejections for new therapies were linked to quality or manufacturing deficiencies.

These statistics highlight the so-called 'valley of death' where promising therapies falter before they ever reach patients. The core of the problem is that early decisions about how a viral vector—the primary delivery vehicle for gene therapies—is designed and produced have profound, long-lasting consequences. A suboptimal choice can lead to manufacturing processes that are difficult to scale, produce low yields, or result in a product that fails to meet stringent purity and potency standards. Correcting these issues late in development can trigger cascading delays, require expensive rework, and jeopardize regulatory approval.

ProBio's new test is engineered to front-load these critical decisions. By offering a comprehensive evaluation in as little as three to five weeks, it allows drug developers to compare different vector designs and packaging strategies early on. This enables them to select the most viable candidate based not just on its biological activity, but also on its practical manufacturability, a factor essential for long-term success.

Technical Precision for a Clearer Path Forward

The new Viral Vector Packaging Test is more than just a simple screen; it's a comprehensive diagnostic tool for a therapy's production potential. The service supports the two most common viral vector types: lentiviral vectors (LVV), which are crucial for CAR-T cell therapies, and adeno-associated viruses (AAV), the workhorse of modern gene therapy.

One of the service's most significant features is its commitment to development-to-CMC continuity. The test utilizes the exact same proprietary cell lines and packaging plasmids that ProBio employs in its later-stage, large-scale Good Manufacturing Practice (GMP) production. This is a critical advantage for clients, as it ensures the material generated during the early test is truly representative of what will be produced for clinical trials. This consistency helps avoid the dreaded issue of 'comparability,' where developers must prove to regulators that a product made with a new process is identical to the one used in earlier studies—a hurdle that can cause significant delays.

The test integrates platform upstream and downstream processes to generate this representative material and then subjects it to a battery of comprehensive quality assessments. These include measuring the physical titer (the concentration of viral particles), genome purity, endotoxin levels, and, where applicable, the full/empty ratio—a crucial metric for AAVs that distinguishes effective, gene-carrying vectors from inactive, empty shells. For more complex programs, the offering incorporates Design of Experiments (DoE) methodology, a systematic approach to rapidly optimize factors like plasmid ratios to maximize vector production.

"Early development choices have lasting impact on the success of cell and gene therapy programs," said Huiyi Zhu, Global Line Manager for Viral Vector at ProBio Inc., in a statement. "This new packaging test reflects our commitment to providing biopharma innovators with practical data, technical confidence, and a clear path forward, using the same systems they can later take into CMC and clinical development."

A Strategic Move in a Competitive Market

The launch of this specialized test is a calculated strategic move for ProBio in the fiercely competitive contract development and manufacturing organization (CDMO) market. The sector has seen massive investment in recent years, with industry giants like Lonza, Catalent, and Thermo Fisher Scientific pouring billions into expanding their viral vector manufacturing capacity to meet soaring demand.

Rather than competing solely on a scale, ProBio is targeting a high-value niche. By focusing on a critical early-stage bottleneck, the company positions itself as a strategic partner that can add value long before a therapy enters large-scale manufacturing. This offering is particularly attractive to the small and mid-sized biotech companies that are the primary engines of innovation in the CGT space but often lack the internal CMC expertise and infrastructure to navigate early development risks.

This new service builds directly on the company's recent investments, including the opening of its 128,000-square-foot, purpose-built viral vector and plasmid DNA facility in Hopewell in 2025. That facility was designed to support clients from early proof-of-concept through to clinical readiness, and this test formalizes the very first step in that end-to-end journey. By providing a clear, de-risked on-ramp to its larger manufacturing services, ProBio aims to build long-term relationships with clients from the earliest stages of their programs.

The ultimate goal of such innovations is to accelerate the delivery of life-saving treatments. By making the development process more efficient and predictable, services like the Viral Vector Packaging Test can help reduce the timeline and cost of bringing new therapies to clinical trials. For a field where every delay can have profound human consequences, this acceleration is not just a commercial advantage—it is a critical step toward fulfilling the immense promise of cell and gene therapy.